Distinct clinical features and outcomes in never‐smokers with nonsmall cell lung cancer who harbor <i>EGFR</i> or <i>KRAS</i> mutations or <i>ALK</i> rearrangement

Abstract

To the authors' knowledge, this was the largest comprehensive and concurrent analysis to date of 3 major oncogenic alterations in a cohort of East Asian never-smokers with NSCLC. Because survival outcomes differed among genotypes, and drugs that target specific alterations currently are available, genetic profiling to identify genotype-specific subsets can lead to successful treatment with appropriate kinase inhibitors.